{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:09:28Z","timestamp":1781154568909,"version":"3.54.1"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T00:00:00Z","timestamp":1382659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>While <jats:styled-content style=\"fixed-case\">fine needle aspiration<\/jats:styled-content> cytology (FNAC) is the mainstay of diagnosis in thyroid nodules, molecular markers of thyroid cancer have recently been shown to be of value in improving the diagnosis and reducing the rates of unnecessary surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A technical method is presented for the assessment of the <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>600 gene mutation in thyroid cancer using a simple adaptation of a commercially available kit. After standard preparation and reporting of conventionally stained alcohol\u2010fixed Papanicolaou or air\u2010dried <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>iemsa\u2010stained slides the coverslip is removed from one slide, the <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content> is extracted and submitted for <jats:styled-content style=\"fixed-case\">PCR<\/jats:styled-content> analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Assessment of the <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content>600 mutational status is feasible in very small quantities of <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>, requiring just greater than 5\u00a0ng per case from a single pre\u2010stained <jats:styled-content style=\"fixed-case\">FNA<\/jats:styled-content> slide using this method. From the 14 cases examined thus far, one <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>hy4\/<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ethesda <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>lass <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content> case (suspicious of malignancy) has been identified with a <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> V600 mutation and this patient, after multidisciplinary discussion, received a total thyroidectomy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on this methodology and other published results for the <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> mutation, we believe that it is now feasible and cost effective for the <jats:styled-content style=\"fixed-case\">UK NHS<\/jats:styled-content> to <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> co\u2010test all <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>hy4\/<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ethesda <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>lass <jats:styled-content style=\"fixed-case\">V<\/jats:styled-content> thyroid <jats:styled-content style=\"fixed-case\">FNA<\/jats:styled-content>s, as the additional cost of <jats:italic><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content><\/jats:italic> testing will still be much less than the cost of submitting all <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>hy4 (Bethesda Class V) patients to a partial and then a later completion thyroidectomy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cyt.12109","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T17:14:10Z","timestamp":1382721250000},"page":"155-159","source":"Crossref","is-referenced-by-count":17,"title":["<i><scp>BRAF<\/scp><\/i> V600 co\u2010testing is technically feasible in conventional thyroid <scp>fine needle aspiration (FNA)<\/scp> cytology smears and can reduce the need for completion thyroidectomy"],"prefix":"10.1111","volume":"25","author":[{"given":"D. N.","family":"Poller","sequence":"first","affiliation":[{"name":"Department of Pathology Queen Alexandra Hospital Cosham Portsmouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Glaysher","sequence":"additional","affiliation":[{"name":"Department of Pathology Queen Alexandra Hospital Cosham Portsmouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.5858\/2010-0664-RAIR.1"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1469"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203208"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0023"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0014"},{"key":"e_1_2_6_7_1","first-page":"90","volume-title":"Diagnostic Endocrine Pathology","author":"Kovacs CM","year":"2012"},{"key":"e_1_2_6_8_1","unstructured":"CrossPA ChandraA GilesTet\u00a0al.Guidance on the reporting of thyroid cytology specimens.http:\/\/www.rcpath.org\/publications-media\/publications\/publications.htm#cyto(accessed 4.9.13)."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPZ33MVMGZKEWU"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-201339"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-013-9240-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2760"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064505"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cyt.12125"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-013-9257-8"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcyt.12109","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cyt.12109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:59:57Z","timestamp":1696363197000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cyt.12109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,25]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/cyt.12109"],"URL":"https:\/\/doi.org\/10.1111\/cyt.12109","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"value":"0956-5507","type":"print"},{"value":"1365-2303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,25]]}}}